| 摘要 |
The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds of Formula (I). The invention also provides pharmaceutical compositions comprising such compounds, the use such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds. Wherein; R<SUP>1 </SUP>is hydrogen, halo, hadroxy, C<SUB>1-4 </SUB>alkyl, or C<SUB>1-4 </SUB>alkoxy; R<SUP>2 </SUP>is C<SUB>3-4 </SUB>alkyl, or C<SUB>3-6</SUB>cycloakyl; R<SUP>3 </SUP>is hydrogen or C<SUB>1-3 </SUB>alkyl: R<SUP>4 </SUP>is -S(O)<SUB>2 </SUB>R<SUP>6 </SUP>or -C(O)R<SUP>7</SUP>; R<SUP>5 </SUP>is hydrogen, C<SUB>1-3</SUB>alkyl, C<SUB>2-3 </SUB>alkyl subtituted with -OH or C<SUB>1-3 </SUB>alkoxy, or -CH<SUB>2</SUB>-pyrydyl; R<SUP>6 </SUP>is C<SUB>1-3 </SUB>alkyl; or R<SUP>5 </SUP>and R<SUP>6 </SUP>taken together from C<SUB>3-4 </SUB>alkylenyl; and R<SUP>7 </SUP>is hydrogen, C<SUB>1-3</SUB>alkyl, or pyrydyl; or pharmaceutically-acceptable salt or solvate or stereoisomer thereof.
|
